Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.64 |
| ▸ | AHCY | P23526 | 10/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | VCP | P55072 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | PI4KA | P42356 | 2/20 | 0.55 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.55 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.55 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30292318 | 1.00 | ADORA2A (0.64) | ADORA2AADORA1AHCYALDH1A1MEN1 | |
| Pyrophosphoric Acid SCHEMBL10602251 | 0.90 | CYP3A4 (0.55) | ADORA2AADORA1AHCYALDH1A1MEN1 | |
| SCHEMBL10474812 | 0.87 | ADORA2A (0.52) | ADORA2AADORA1AHCYCYP3A4PI4KA | |
| SCHEMBL22193338 | 0.86 | ADORA2A (0.69) | ADORA2AADORA1AHCYLMNASMN1; SMN2 | |
| SCHEMBL30292313 | 0.86 | ADORA2A (0.51) | ADORA2AADORA1AHCYALDH1A1MEN1 | |
| SCHEMBL10601866 | 0.86 | ENPP1 (0.53) | ADORA2AADORA1AHCYALDH1A1MEN1 | |
| SCHEMBL10818140 | 0.85 | ADORA2A (0.50) | ADORA2AADORA1AHCYALDH1A1MEN1 | |
| SCHEMBL14472999 | 0.84 | AHCY (0.60) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL10284145 | 0.84 | AHCY (0.60) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL2293264 | 0.83 | ADORA2A (0.68) | ADORA2AADORA1AHCYALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0049072-A1 | Guanine compounds and their use for the preparation of anti-viral agents | SYNTEX (U.S.A.) INC. (US) | 1982-04-07 | — | — | EP | claimed |
| US-20230330126-A1 | MODIFIED ADENOSINE NUCLEOSIDE FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | IACHETTINI GIAMPIETRO (IT) | 2023-10-19 | — | — | US | disclosed |
| US-20090203636-A1 | Prevention and Treatment of Cancer and Other Diseases | ALT SOLUTIONS, INC. | 2009-08-13 | — | — | US | disclosed |
| US-20090203636-A1 | Prevention and Treatment of Cancer and Other Diseases | ALT SOLUTIONS, INC. | 2009-08-13 | — | — | US | disclosed |
| US-20090203636-A1 | Prevention and Treatment of Cancer and Other Diseases | ALT SOLUTIONS, INC. | 2009-08-13 | — | — | US | disclosed |
| EP-2001488-A2 | PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES | Alt Solutions, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007106561-A2 | PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES | ALT SOLUTIONS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-5250535-A | Herpes virus; nontoxic; side effect reduction; humans and veterinary medicine | SYNTEX INC. (US) | 1993-10-05 | — | — | US | disclosed |
| US-5157120-A | Guanine derivatives | SYNTEX (U.S.A.) INC. (US) | 1992-10-20 | — | — | US | disclosed |
| EP-0138656-B1 | CYCLIC PYROPHOSPHATES OF PURINE AND PYRIMIDINE ACYCLONUCLEOSIDES, THEIR PREPARATION AND THEIR APPLICATION IN ANTI-VIRAL COMPOSITIONS | MERCK & CO. INC. (US) | 1989-09-27 | — | — | EP | disclosed |
| US-4612314-A | Substituted 9-(1 or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl) purines as antiviral agent | SYNTEX (U.S.A.) INC. (US) | 1986-09-16 | — | — | US | disclosed |
| US-4609661-A | HERPES VIRUS | SYNTEX (U.S.A.) INC. (US) | 1986-09-02 | — | — | US | disclosed |
| US-4556659-A | Substituted 9-(1-0- or 3-0-monosubstituted or 1,3-Di-0-substituted propoxymethyl)-purines as antiviral agents | SYNTEX (U.S.A.) INC. (US) | 1985-12-03 | — | — | US | disclosed |
| EP-0138656-A1 | Cyclic pyrophosphates of purine and pyrimidine acyclonucleosides, their preparation and their application in anti-viral compositions | MERCK & CO. INC. (US) | 1985-04-24 | — | — | EP | disclosed |
| US-4501744-A | Substituted-aza-cytosine compounds and anti-viral uses thereof | ENS BIO LOGICALS INC. (CA) | 1985-02-26 | — | — | US | disclosed |
| US-4461757-A | 2-(N,N-DIALKYLAMINO-METHYLENE)-9-((2-HYDROXY-1 -(HYDROXYMETHYL)ETHOXY)METHYL)GUANINE | ENS BIO LOGICALS INC. (CA) | 1984-07-24 | — | — | US | disclosed |
| EP-0105135-A1 | Substituted 9-(1-0- or 3-0-monosubstituted or 1,3-di-0-substituted 1,3 dihydroxy-2-propoxymethyl) purines as antiviral agents | SYNTEX (U.S.A.) INC. (US) | 1984-04-11 | — | — | EP | disclosed |
| EP-0085424-A2 | Substituted 9-(1 or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl)purines as antiviral agent | SYNTEX (U.S.A.) INC. (US) | 1983-08-10 | — | — | EP | disclosed |
| US-4347360-A | Ring open nucleoside analogues | ENS BIO LOGICALS INC. (CA) | 1982-08-31 | — | — | US | disclosed |
| EP-0049072-A1 | Guanine compounds and their use for the preparation of anti-viral agents | SYNTEX (U.S.A.) INC. (US) | 1982-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203636-A1 | Prevention and Treatment of Cancer and Other Diseases | TERT, POLRMT, RNASE1 | ADORA2A 1461/4885ADORA1 2194/4885AHCY 476/4885 |
| US-20230330126-A1 | MODIFIED ADENOSINE NUCLEOSIDE FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA1 5/4885AHCY 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.